BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Consensus Rating of “Hold” by Brokerages

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have been assigned an average recommendation of “Hold” from the four analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $11.00.

Several analysts have recently commented on the stock. Wall Street Zen downgraded shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Rodman & Renshaw assumed coverage on shares of BioXcel Therapeutics in a report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 price objective on the stock. Zacks Research raised shares of BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Monday, April 20th. Finally, HC Wainwright dropped their price objective on shares of BioXcel Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd.

Institutional Trading of BioXcel Therapeutics

Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its holdings in shares of BioXcel Therapeutics by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock valued at $51,000 after acquiring an additional 6,120 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in BioXcel Therapeutics by 38.5% during the third quarter. Jones Financial Companies Lllp now owns 36,000 shares of the company’s stock worth $97,000 after buying an additional 10,000 shares in the last quarter. State Street Corp boosted its holdings in BioXcel Therapeutics by 19.9% during the fourth quarter. State Street Corp now owns 63,218 shares of the company’s stock worth $101,000 after buying an additional 10,500 shares in the last quarter. Diversify Wealth Management LLC purchased a new stake in BioXcel Therapeutics during the second quarter worth $27,000. Finally, HRT Financial LP purchased a new stake in BioXcel Therapeutics during the fourth quarter worth $28,000. 30.68% of the stock is owned by hedge funds and other institutional investors.

BioXcel Therapeutics Trading Up 0.8%

Shares of BioXcel Therapeutics stock opened at $1.20 on Friday. BioXcel Therapeutics has a 12-month low of $1.01 and a 12-month high of $8.08. The firm has a market capitalization of $37.06 million, a price-to-earnings ratio of -0.21 and a beta of 0.30. The firm’s 50 day simple moving average is $1.15 and its two-hundred day simple moving average is $1.49.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.01). The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.38 million. On average, sell-side analysts predict that BioXcel Therapeutics will post -2.07 EPS for the current fiscal year.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.